NCT05490888View on ClinicalTrials.gov

Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics

PHASE1RecruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

January 3, 2022

Primary Completion Date

May 31, 2026

Study Completion Date

June 30, 2026

Conditions
Cirrhosis, LiverLiver FibrosisAscites Hepatic
Interventions
DRUG

PHIN-214 Subcutaneous injection

subcutaneous injection(s) with PHIN-214 terlipressin derivative

Trial Locations (9)

19104

RECRUITING

University of Pennsylvania, Philadelphia

44195

RECRUITING

Cleveland Clinic, Cleveland

55905

RECRUITING

Mayo Clinic, Rochester

70072

RECRUITING

Tandem Clinical Research, Marrero

75203

RECRUITING

Methodist Health System, Dallas Medical Center, Dallas

75216

RECRUITING

VA North Texas Healthcare System, Dallas

78215

RECRUITING

Texas Liver Institute, San Antonio

85224

RECRUITING

Arizona Liver Health, Chandler

92118

RECRUITING

Southern California Research Center, Coronado

Sponsors

Lead Sponsor

PharmaIN
All Listed Sponsors
lead

PharmaIN

INDUSTRY

NCT05490888 - Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics | Biotech Hunter | Biotech Hunter